Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present the latest clinical study results of its novel Nectin‑4‑targeting ADC, 9MW2821, for triple‑negative breast cancer in an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Annual Congress in Madrid, Spain, October 23-27, 2026.

Oral Presentation

Title: Bulumtatug Fuvedotin (BFv, 9MW2821), a Nectin-4-Directed Antibody-Drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer (la/mTNBC) Previously Treated with Topoisomerase I Inhibitor (Topl)-Based ADCs: Results from a Phase 2 Study.

Abstract No.: 4640RO

Presenter: Prof. ZHANG Jian, Chief Physician, doctoral supervisor (Fudan University Shanghai Cancer Center)

Session: Breast cancer, advanced stage

Session Date and Time: 10/26/2026, 10:15 AM-11:45AM (local time)